|
1
|
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
|
J Leukoc Biol
|
2013
|
1.90
|
|
2
|
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.
|
J Clin Oncol
|
2014
|
1.47
|
|
3
|
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
|
Oncoimmunology
|
2014
|
1.22
|
|
4
|
Pathways and therapeutic targets in melanoma.
|
Oncotarget
|
2014
|
1.17
|
|
5
|
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
|
Front Immunol
|
2015
|
1.04
|
|
6
|
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
|
Curr Oncol Rep
|
2013
|
0.94
|
|
7
|
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
|
Toxins (Basel)
|
2014
|
0.92
|
|
8
|
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.
|
Curr Oncol Rep
|
2014
|
0.89
|
|
9
|
The past, present and future of immunotherapy against tumor.
|
Transl Lung Cancer Res
|
2015
|
0.85
|
|
10
|
The tumor microenvironment in esophageal cancer.
|
Oncogene
|
2016
|
0.83
|
|
11
|
Immunological off-target effects of imatinib.
|
Nat Rev Clin Oncol
|
2016
|
0.81
|
|
12
|
Current trends in glioblastoma multiforme treatment: radiation therapy and immune checkpoint inhibitors.
|
Brain Tumor Res Treat
|
2013
|
0.80
|
|
13
|
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
|
Semin Immunol
|
2016
|
0.78
|
|
14
|
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.
|
Trends Immunol
|
2016
|
0.75
|